Plain-English translation of NCT07228273 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding to a combination of three chemotherapy drugs (, , and ) works better than the standard two-drug chemotherapy approach for treating newly diagnosed acute myeloid leukemia. Researchers want to see if this new four-drug combination helps more patients reach a deeper remission—where leukemia cells are no longer detectable in bone marrow tests—compared to current standard treatment.
Acute myeloid leukemia is a serious blood cancer, and while standard chemotherapy helps many patients, doctors are looking for ways to achieve better and longer-lasting remissions. This medication may help patients reach deeper remission and potentially improve their long-term survival.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you'll be randomly assigned to receive either the new four-drug combination or standard chemotherapy. Both groups receive chemotherapy in cycles over several weeks, followed by additional consolidation treatment cycles. You'll have frequent doctor visits, blood tests, and bone marrow biopsies to monitor how well the treatment is working. The trial also evaluates whether you proceed to stem cell transplant, and if you do, doctors will continue tracking your recovery, side effects, and long-term health for months after transplant.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States